BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 8013572)

  • 1. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
    Sierra J; Terol MJ; Urbano-Ispizua A; Rovira M; Marin P; Carreras E; Batlle M; Rozman C
    Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
    Locatelli F; Pession A; Zecca M; Bonetti F; Prete L; Carrà AM; Prete A; Montagna D; Comoli P; Taibi RM; Paolucci G
    Bone Marrow Transplant; 1996 Jan; 17(1):31-7. PubMed ID: 8673051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.
    Nemunaitis J; Rosenfeld CS; Ash R; Freedman MH; Deeg HJ; Appelbaum F; Singer JW; Flomenberg N; Dalton W; Elfenbein GJ
    Bone Marrow Transplant; 1995 Jun; 15(6):949-54. PubMed ID: 7581096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant GM-CSF in patients with poor graft function after bone marrow transplantation.
    Klingemann HG; Eaves AC; Barnett MJ; Reece DE; Shepherd JD; Belch AR; Brandwein JM; Langleben A; Koch PA; Phillips GL
    Clin Invest Med; 1990 Apr; 13(2):77-81. PubMed ID: 2191816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
    Madero L; Díaz MA; Ortega JJ; Olive T; Martínez A; Badell I; Muñoz A; Gómez P
    Haematologica; 1999 Feb; 84(2):133-7. PubMed ID: 10091411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse.
    Richard C; Baro J; Bello-Fernandez C; Hermida G; Calavia J; Olalla I; Alsar MJ; Loyola I; Cuadrado MA; Iriondo A
    Bone Marrow Transplant; 1995 May; 15(5):721-6. PubMed ID: 7670401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.
    Ippoliti C; Przepiorka D; Giralt S; Andersson BS; Wallerstein RO; Gutterman J; Deisseroth AB; Champlin RE
    Bone Marrow Transplant; 1993 Jan; 11(1):55-9. PubMed ID: 8094309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effects of recombinant human granulocyte colony-stimulating factor in leukemia patients: a phase I/II study.
    Teshima H; Ishikawa J; Kitayama H; Yamagami T; Hiraoka A; Nakamura H; Shibata H; Masaoka T; Takaku F
    Exp Hematol; 1989 Sep; 17(8):853-8. PubMed ID: 2475358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
    Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ
    Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.
    Colombat P; Delain M; Desbois I; Domenech J; Binet C; Tabah I; Lamagnere JP; Linassier C
    Bone Marrow Transplant; 1996 Aug; 18(2):293-9. PubMed ID: 8864437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous bone marrow transplantation.
    Nemunaitis JJ; Singer JW; Sanders JE
    Bone Marrow Transplant; 1991; 7 Suppl 3():24-7. PubMed ID: 1855082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma.
    Fay JW; Bernstein SH
    Semin Oncol; 1996 Apr; 23(2 Suppl 4):22-7. PubMed ID: 8600545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution.
    Calderwood S; Doyle JJ; Hitzler JK; Saunders EF; Freedman MH
    Bone Marrow Transplant; 1996 Jul; 18(1):87-91. PubMed ID: 8832000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.